PHARMAKINETICS LABORATORIES INC
10-Q, EX-27, 2000-11-14
TESTING LABORATORIES
Previous: PHARMAKINETICS LABORATORIES INC, 10-Q, 2000-11-14
Next: INTERFERON SCIENCES INC, 10-Q, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SEC FORM
10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-END>                               SEP-30-2000
<CASH>                                          92,228
<SECURITIES>                                         0
<RECEIVABLES>                                1,574,278
<ALLOWANCES>                                   110,002
<INVENTORY>                                    543,228
<CURRENT-ASSETS>                             2,308,075
<PP&E>                                       7,213,966
<DEPRECIATION>                               3,360,183
<TOTAL-ASSETS>                               6,251,170
<CURRENT-LIABILITIES>                        2,268,113
<BONDS>                                              0
                                0
                                  5,210,938
<COMMON>                                        12,481
<OTHER-SE>                                 (1,240,362)
<TOTAL-LIABILITY-AND-EQUITY>                 6,251,170
<SALES>                                      2,641,846
<TOTAL-REVENUES>                             2,652,307
<CGS>                                        2,009,478
<TOTAL-COSTS>                                2,567,301
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,151
<INCOME-PRETAX>                                 80,430
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             80,430
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    80,430
<EPS-BASIC>                                       0.03
<EPS-DILUTED>                                     0.02


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission